These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Recent advances in glucokinase activators for the treatment of type 2 diabetes. Pal M Drug Discov Today; 2009 Aug; 14(15-16):784-92. PubMed ID: 19520181 [TBL] [Abstract][Full Text] [Related]
6. Structural basis for allosteric regulation of the monomeric allosteric enzyme human glucokinase. Kamata K; Mitsuya M; Nishimura T; Eiki J; Nagata Y Structure; 2004 Mar; 12(3):429-38. PubMed ID: 15016359 [TBL] [Abstract][Full Text] [Related]
7. A report of 2 new cases of MODY2 and review of the literature: implications in the search for type 2 diabetes drugs. Shammas C; Neocleous V; Phelan MM; Lian LY; Skordis N; Phylactou LA Metabolism; 2013 Nov; 62(11):1535-42. PubMed ID: 23890519 [TBL] [Abstract][Full Text] [Related]
8. Recent updates on glucokinase activators for the treatment of type 2 diabetes mellitus. Grewal AS; Sekhon BS; Lather V Mini Rev Med Chem; 2014; 14(7):585-602. PubMed ID: 25052034 [TBL] [Abstract][Full Text] [Related]
10. GKAs for diabetes therapy: why no clinically useful drug after two decades of trying? Matschinsky FM Trends Pharmacol Sci; 2013 Feb; 34(2):90-9. PubMed ID: 23305809 [TBL] [Abstract][Full Text] [Related]
11. Novel, highly potent systemic glucokinase activators for the treatment of Type 2 Diabetes Mellitus. Xu J; Lin S; Myers RW; Addona G; Berger JP; Campbell B; Chen HS; Chen Z; Eiermann GJ; Elowe NH; Farrer BT; Feng W; Fu Q; Kats-Kagan R; Kavana M; Malkani S; McMasters DR; Mitra K; Pachanski MJ; Tong X; Trujillo ME; Xu L; Zhang B; Zhang F; Zhang R; Parmee ER Bioorg Med Chem Lett; 2017 May; 27(9):2069-2073. PubMed ID: 28284804 [TBL] [Abstract][Full Text] [Related]
12. Molecular modeling and identification of novel glucokinase activators through stepwise virtual screening. Behera PM; Behera DK; Satpati S; Agnihotri G; Nayak S; Padhi P; Dixit A J Mol Graph Model; 2015 Apr; 57():122-30. PubMed ID: 25723349 [TBL] [Abstract][Full Text] [Related]
14. Reversal of type 1 diabetes by engineering a glucose sensor in skeletal muscle. Mas A; Montané J; Anguela XM; Muñoz S; Douar AM; Riu E; Otaegui P; Bosch F Diabetes; 2006 Jun; 55(6):1546-53. PubMed ID: 16731816 [TBL] [Abstract][Full Text] [Related]
15. From clinicogenetic studies of maturity-onset diabetes of the young to unraveling complex mechanisms of glucokinase regulation. Sagen JV; Odili S; Bjørkhaug L; Zelent D; Buettger C; Kwagh J; Stanley C; Dahl-Jørgensen K; de Beaufort C; Bell GI; Han Y; Grimsby J; Taub R; Molven A; Søvik O; Njølstad PR; Matschinsky FM Diabetes; 2006 Jun; 55(6):1713-22. PubMed ID: 16731834 [TBL] [Abstract][Full Text] [Related]
16. Banting Lecture 1995. A lesson in metabolic regulation inspired by the glucokinase glucose sensor paradigm. Matschinsky FM Diabetes; 1996 Feb; 45(2):223-41. PubMed ID: 8549869 [TBL] [Abstract][Full Text] [Related]
17. Glucokinase activators in diabetes management. Coghlan M; Leighton B Expert Opin Investig Drugs; 2008 Feb; 17(2):145-67. PubMed ID: 18230050 [TBL] [Abstract][Full Text] [Related]
18. Small molecule glucokinase activators as glucose lowering agents: a new paradigm for diabetes therapy. Guertin KR; Grimsby J Curr Med Chem; 2006; 13(15):1839-43. PubMed ID: 16787225 [TBL] [Abstract][Full Text] [Related]
19. The potential role of glucokinase activator SHP289-04 in anti-diabetes and hepatic protection. Lei L; Liu S; Li Y; Song H; He L; Liu Q; Sun S; Li Y; Feng Z; Shen Z Eur J Pharmacol; 2018 May; 826():17-23. PubMed ID: 29477658 [TBL] [Abstract][Full Text] [Related]
20. Mutants of glucokinase cause hypoglycaemia- and hyperglycaemia syndromes and their analysis illuminates fundamental quantitative concepts of glucose homeostasis. Davis EA; Cuesta-Muñoz A; Raoul M; Buettger C; Sweet I; Moates M; Magnuson MA; Matschinsky FM Diabetologia; 1999 Oct; 42(10):1175-86. PubMed ID: 10525657 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]